Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.
Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.
复制标题
DOI：
10.3390/biomedicines11020338
复制
发表时间：
2023-01-25
期刊：
影响因子：
4.7
通讯作者：
中科院分区：
文献类型：
--
作者：
与没有镰状细胞病 (SCD) 的人相比，患有镰状细胞病 (SCD) 的人因呼吸道感染（包括 COVID-19）而罹患严重疾病和死亡的风险更大（美国疾病控制与预防中心）。 SCD 中的血管闭塞危象 (VOC) 和严重的 SARS-CoV-2 感染均以内皮损伤、补体激活、炎症脂质风暴、血小板激活、血小板-白细胞粘附和凝血级联激活介导的血栓炎症为特征。值得注意的是，包括血栓素 A2 在内的脂质介质在严重的 COVID-19 和 SCD 中显着增加。此外，内皮细胞和巨噬细胞释放血栓素A2会刺激血小板释放微泡，这是多细胞粘附和血栓炎症的先兆。目前，针对 SCD 或 COVID-19 急性危象期间血小板中性粒细胞激活和血栓炎症的治疗策略有限。然而，由于 SCD 和 COVID-19 的血栓炎症病理学之间有许多相似之处，针对一种疾病的治疗可能对另一种疾病有效。因此，COVID-19大流行引发的临床前和临床研究，包括抗血栓药物的临床试验，可能适用于VOC。在这里，我们首先概述 SCD 和 COVID-19 之间的相似之处；其次，回顾脂质介质在这些疾病发病机制中的作用；最后，研究这两种疾病的治疗靶点和潜在治疗方法。
People with sickle cell disease (SCD) are at greater risk of severe illness and death from respiratory infections, including COVID-19, than people without SCD (Centers for Disease Control and Prevention, USA). Vaso-occlusive crises (VOC) in SCD and severe SARS-CoV-2 infection are both characterized by thrombo-inflammation mediated by endothelial injury, complement activation, inflammatory lipid storm, platelet activation, platelet-leukocyte adhesion, and activation of the coagulation cascade. Notably, lipid mediators, including thromboxane A2, significantly increase in severe COVID-19 and SCD. In addition, the release of thromboxane A2 from endothelial cells and macrophages stimulates platelets to release microvesicles, which are harbingers of multicellular adhesion and thrombo-inflammation. Currently, there are limited therapeutic strategies targeting platelet-neutrophil activation and thrombo-inflammation in either SCD or COVID-19 during acute crisis. However, due to many similarities between the pathobiology of thrombo-inflammation in SCD and COVID-19, therapies targeting one disease may likely be effective in the other. Therefore, the preclinical and clinical research spurred by the COVID-19 pandemic, including clinical trials of anti-thrombotic agents, are potentially applicable to VOC. Here, we first outline the parallels between SCD and COVID-19; second, review the role of lipid mediators in the pathogenesis of these diseases; and lastly, examine the therapeutic targets and potential treatments for the two diseases.
登录
查看更多内容
DOI：
10.3904/kjim.2011.26.1.8
发表时间：
2011-03
期刊：
The Korean journal of internal medicine
影响因子：
--
作者：
Arima M;Fukuda T
通讯作者：
Fukuda T
影响因子：
12.3
作者：
Aschenbrenner AC;Mouktaroudi M;Krämer B;Oestreich M;Antonakos N;Nuesch-Germano M;Gkizeli K;Bonaguro L;Reusch N;Baßler K;Saridaki M;Knoll R;Pecht T;Kapellos TS;Doulou S;Kröger C;Herbert M;Holsten L;Horne A;Gemünd ID;Rovina N;Agrawal S;Dahm K;van Uelft M;Drews A;Lenkeit L;Bruse N;Gerretsen J;Gierlich J;Becker M;Händler K;Kraut M;Theis H;Mengiste S;De Domenico E;Schulte-Schrepping J;Seep L;Raabe J;Hoffmeister C;ToVinh M;Keitel V;Rieke G;Talevi V;Skowasch D;Aziz NA;Pickkers P;van de Veerdonk FL;Netea MG;Schultze JL;Kox M;Breteler MMB;Nattermann J;Koutsoukou A;Giamarellos-Bourboulis EJ;Ulas T;German COVID-19 Omics Initiative (DeCOI)
通讯作者：
German COVID-19 Omics Initiative (DeCOI)
影响因子：
8.2
作者：
Abadpour, Shadab;Tyrberg, Bjorn;Winzell, Maria Sorhede
通讯作者：
Winzell, Maria Sorhede
阻断血栓素 A2 受体可减轻香烟烟雾引起的气道粘液过度产生
影响因子：
5
作者：
An, Jing;Li, Ji-Qiong;Wen, Fu-Qiang
通讯作者：
Wen, Fu-Qiang
影响因子：
158.5
作者：
Ackermann, Maximilian;Verleden, Stijn E.;Jonigk, Danny
通讯作者：
Jonigk, Danny